Rhythm Pharmaceuticals Inc (RYTM.OQ)
RYTM.OQ on NASDAQ Stock Exchange Global Market
22.19USD
20 Apr 2018
22.19USD
20 Apr 2018
Change (% chg)
$-0.23 (-1.03%)
$-0.23 (-1.03%)
Prev Close
$22.42
$22.42
Open
$22.24
$22.24
Day's High
$22.44
$22.44
Day's Low
$21.93
$21.93
Volume
11,164
11,164
Avg. Vol
38,998
38,998
52-wk High
$33.80
$33.80
52-wk Low
$16.89
$16.89
About
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent,... (more)
Overall
| Beta: | -- |
| Market Cap(Mil.): | $685.07 |
| Shares Outstanding(Mil.): | 27.13 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| RYTM.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 84.02 | 32.74 |
| EPS (TTM): | -1.24 | -- | -- |
| ROI: | -- | 1.58 | 14.38 |
| ROE: | -- | 2.41 | 16.07 |
BRIEF-Rhythm Pharma Announces Licensing Agreement With Takeda
* RHYTHM PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF PRECLINICAL TREATMENT FOR PRADER-WILLI SYNDROME
BRIEF-Rhythm Pharmaceuticals Reports Qtrly Loss Per Share $0.41
* RHYTHM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS
BRIEF-Rhythm Pharmaceuticals Announces Progress In Clinical Development Of Setmelanotide
* RHYTHM PHARMACEUTICALS ANNOUNCES PROGRESS IN CLINICAL DEVELOPMENT OF SETMELANOTIDE FOR TREATMENT OF RARE GENETIC DISORDERS OF OBESITY
BRIEF-Rhythm Pharmaceuticals reports Q3 loss of $1.78/shr
* Rhythm Pharmaceuticals reports third quarter 2017 financial results
Estimates